CR20230109A - Sistema de liberación de fármacos descongestivos y bilastina - Google Patents
Sistema de liberación de fármacos descongestivos y bilastinaInfo
- Publication number
- CR20230109A CR20230109A CR20230109A CR20230109A CR20230109A CR 20230109 A CR20230109 A CR 20230109A CR 20230109 A CR20230109 A CR 20230109A CR 20230109 A CR20230109 A CR 20230109A CR 20230109 A CR20230109 A CR 20230109A
- Authority
- CR
- Costa Rica
- Prior art keywords
- decongestant
- bilastine
- layer
- delivery system
- drug delivery
- Prior art date
Links
- 239000000850 decongestant Substances 0.000 title abstract 4
- 238000012377 drug delivery Methods 0.000 title 1
- 229960004314 bilastine Drugs 0.000 abstract 3
- ACCMWZWAEFYUGZ-UHFFFAOYSA-N bilastine Chemical compound N=1C2=CC=CC=C2N(CCOCC)C=1C(CC1)CCN1CCC1=CC=C(C(C)(C)C(O)=O)C=C1 ACCMWZWAEFYUGZ-UHFFFAOYSA-N 0.000 abstract 3
- 229920002678 cellulose Polymers 0.000 abstract 2
- 239000001913 cellulose Substances 0.000 abstract 2
- 238000013270 controlled release Methods 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 abstract 1
- 239000011159 matrix material Substances 0.000 abstract 1
- 239000006186 oral dosage form Substances 0.000 abstract 1
- 239000008203 oral pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pulmonology (AREA)
- Emergency Medicine (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Otolaryngology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a una composición farmacéutica oral multicapa que comprende un núcleo matricial, que comprende un descongestivo y una combinación de al menos dos derivados de celulosa, una primera capa que comprende un derivado de celulosa y una segunda capa opcional que comprende bilastina. La presente invención proporciona una forma de dosificación oral que comprende un fármaco descongestivo y bilastina con un perfil reproducible caracterizado por una liberación controlada del descongestivo durante un periodo superior a doce horas y preferiblemente al menos 16 horas y una liberación inmediata de bilastina después de la administración oral. La invención contempla además usos médicos de la misma.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20382701 | 2020-07-30 | ||
| PCT/EP2021/071244 WO2022023463A1 (en) | 2020-07-30 | 2021-07-29 | Decongestant drug delivery system |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20230109A true CR20230109A (es) | 2023-05-11 |
Family
ID=72039495
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20230109A CR20230109A (es) | 2020-07-30 | 2021-07-29 | Sistema de liberación de fármacos descongestivos y bilastina |
Country Status (8)
| Country | Link |
|---|---|
| EP (1) | EP4188339A1 (es) |
| CL (1) | CL2023000262A1 (es) |
| CO (1) | CO2023002166A2 (es) |
| CR (1) | CR20230109A (es) |
| DO (1) | DOP2023000017A (es) |
| EC (1) | ECSP23010160A (es) |
| PE (1) | PE20231844A1 (es) |
| WO (1) | WO2022023463A1 (es) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4990535A (en) | 1989-05-03 | 1991-02-05 | Schering Corporation | Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine |
| ES2048109B1 (es) | 1992-07-20 | 1994-12-16 | Espanola Prod Quimicos | Procedimiento de preparacion de nuevos derivados piperidicos del bencimidazol. |
| US5314697A (en) | 1992-10-23 | 1994-05-24 | Schering Corporation | Stable extended release oral dosage composition comprising loratadine and pseudoephedrine |
| ES2124167B1 (es) | 1996-06-04 | 1999-09-16 | Espanola Prod Quimicos | Nuevos derivados del bencimidazol con actividad antihistaminica. |
| WO2001045668A2 (en) | 1999-12-20 | 2001-06-28 | Schering Corporation | Stable extended release oral dosage composition comprising pseudoephedrine and desloratadine |
| CA2508722A1 (en) * | 2002-12-11 | 2004-06-24 | Pfizer Products Inc. | Controlled-release of an active substance into a high fat environment |
| US20070014855A1 (en) * | 2005-07-12 | 2007-01-18 | Rahul Gawande S | Stable desloratadine compositions |
| NZ573174A (en) * | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| MX2011005899A (es) | 2011-06-03 | 2013-01-10 | Senosiain S A De C V Lab | Composicion farmacéutica con antihistamínico no sedante y combinaciones. |
| CN104000822A (zh) * | 2014-06-10 | 2014-08-27 | 合肥医工医药有限公司 | 一种含有比拉斯汀的复方感冒药物组合物 |
| MX2015003937A (es) * | 2015-03-26 | 2016-09-26 | Alparis Sa De Cv | Composicion farmaceutica de antihistaminico no sedante e inmunosupresor antiinflamatorio. |
-
2021
- 2021-07-29 CR CR20230109A patent/CR20230109A/es unknown
- 2021-07-29 PE PE2023000151A patent/PE20231844A1/es unknown
- 2021-07-29 WO PCT/EP2021/071244 patent/WO2022023463A1/en active Application Filing
- 2021-07-29 EP EP21755715.6A patent/EP4188339A1/en active Pending
-
2023
- 2023-01-26 CL CL2023000262A patent/CL2023000262A1/es unknown
- 2023-01-27 DO DO2023000017A patent/DOP2023000017A/es unknown
- 2023-02-13 EC ECSENADI202310160A patent/ECSP23010160A/es unknown
- 2023-02-27 CO CONC2023/0002166A patent/CO2023002166A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PE20231844A1 (es) | 2023-11-21 |
| CO2023002166A2 (es) | 2023-06-09 |
| ECSP23010160A (es) | 2023-03-31 |
| DOP2023000017A (es) | 2023-02-28 |
| WO2022023463A1 (en) | 2022-02-03 |
| EP4188339A1 (en) | 2023-06-07 |
| CL2023000262A1 (es) | 2023-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101534809B (zh) | 取代的2-氨基1,2,3,4-四氢化萘在制备预防、减轻和/或治疗各类疼痛的药物中的用途 | |
| JP2020079273A (ja) | 神経抑制性ケタミンの単層による経口投与 | |
| JP2009525985A5 (es) | ||
| NO20043723L (no) | Farmasoytisk doseringform for avgivese gjennom slimhinner | |
| CA2934595A1 (en) | Composition and method for aiding sleep | |
| RU2007122410A (ru) | Композиция, содержащая основу или покрытие для замедленного высвобождения и антагонист nmda-рецептора, способ введения такого nmda-антагониста субъекту | |
| EP1849462A3 (en) | A method of alleviating signs and symptons of Spasticity | |
| JP2010501576A5 (es) | ||
| CA3135877A1 (en) | Transdermal medicament | |
| AU2019101470A4 (en) | Melatonin mini-tablets and method of manufacturing the same | |
| KR20090045149A (ko) | 류마티스 질환의 지연-방출형 글루코코르티코이드 치료제 | |
| CR20230109A (es) | Sistema de liberación de fármacos descongestivos y bilastina | |
| AR048318A1 (es) | Formulaciones de matriz orales que comprenden licarbazepina | |
| Sharma et al. | Effect of gabapentin in postoperative pain, nausea and vomiting in patients undergoing laparoscopic cholecystectomy | |
| AR083893A1 (es) | Uso de una composicion farmaceutica que comprende (s) (3-(1-(1h-imidazol-4-il)etil)-2-metilfenil)metanol para preparar un medicamento topico de utilidad en la reduccion de la presion intraocular y articulo de manufactura correspondiente | |
| Hodgson | Cancer pain management in a hospital setting | |
| Atlas et al. | Haloperidol for the treatment of ketamine-induced emergence delirium | |
| CA2996327A1 (en) | Novel composition for improved sleep | |
| James | Chronopharmaceutical drug delivery system of anti-hypertensive drugs: process optimization and biopharmaceutical evaluation | |
| Terman et al. | Controlled release melatonin in a physiological washout profile | |
| Talati et al. | Rotigotine: the first transdermal nonergot-derived dopamine agonist for the treatment of Parkinson disease [corrected][published erratum appears in FORMULARY 2008 Jan; 43 (1): 12]. | |
| RU2015128914A (ru) | Составы лоразепама с контролируемым высвобождением | |
| WO2020096569A1 (en) | Composition and method for aiding sleep | |
| CN111467357A (zh) | 一种药物组合物及其制备方法和用途 | |
| JP2021517910A (ja) | タシメルテオンを用いる障害の治療 |